Cogentix Medical (NASDAQ: CGNT) said today that it invested $2 million in privately-held Vensica Medical and its ultrasound-based, needle-free drug delivery device, VensiCare.
Israel-based Vensica Medical is developing its VensiCare device as a way to deliver botulinum toxin to treat overactive bladder. The company also has IP for the delivery of oncology agents to the bladder, according to Cogentix.
Get the full story at our sister site, Drug Delivery Business News.
The post Cogentix backs Vensica Medical and its needle-free drug delivery system appeared first on MassDevice.
from MassDevice http://ift.tt/2fBt96z
Cap comentari:
Publica un comentari a l'entrada